This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Sector Weekly Rewind

BOSTON ( TheStreet) -- Adam Feuerstein's take on the biotech week that was Nov. 1, 2010:

The week's best-performing stocks in the sector: Avanir Pharmaceuticals (SYMBOL) (+98%), Aastrom Biosciences (ASTM) (+39%), Jazz Pharmaceuticals (JAZZ) (+34%), Repros Therapeutics (RPRX) (+23%), and Curis (CRIS) (+19%).

It was Hep C-apalooza in Boston this week at the American Association for the Study of Liver Disease (AASLD) annual meeting, which included important updates from Vertex Pharmaceuticals (VRTX - Get Report), Merck (MRK) and others.

One guy who didn't enjoy his time at AASLD was Dr. Yves Benhamou, arrested on criminal fraud charges for allegedly tipping off a hedge fund with insider information about negative clinical trial results.

Bad Medicine: When Doctors Tip Off Wall Street.

Cell Therapeutics (CTIC) submitted the lymphoma drug pixantrone for European approval.

The top FDA drug approval pickers.

GenVec (GNVC) received no bidders for the company.

Fear the Beard! The San Francisco Giants win the World Series!

FDA approves Cadence Pharmaceuticals' (CADX) injectable painkiller Ofirmev but investors sell the stock.

FDA review of Bristol-Myers Squibb's (BMY) melanoma drug Ipilimumab extended three months. The new approval decision date is March 25, 2010.

Questcor Pharmaceuticals (QCOR) launches Acthar as a treatment for infantile spasms.

The week's worst-performing stocks: Biodel (BIOD) (-48%), Angiotech Pharmaceuticals (ANPI) (-44%), AspenBio Pharma (APPY) (-29%), ARYx Therapeutics (ARYX) (-20%), and Anthera Pharmaceuticals (ANTH) (-15%).

Adventrx Pharmaceuticals (ANX) submits FDA approval application for the chemotherapy drug exelbine (ANX-530).

Biogen Idec (BIIB - Get Report) fires 15% of its workforce as part of a corporate restructuring and cost-cutting plan.

FDA Drug Approvals for October

Dendreon (DNDN): Provenge sales, guidance fall short.

Exact Sciences (EXAS) prices 10 million shares at $6 a share.

MannKind (MNKD) Accused of Data Fraud Coverup.

This week's Biotech Stock Mailbag: Orexigen Therapeutics (OREX), Exact Sciences, Spectrum Pharmaceuticals (SPPI), Avanir Pharmaceuticals and MannKind.

Savient (SVNT) Pharmaceuticals to launch gout drug Krystexxa on Nov. 30.

Roche offers secret rebates to doctors who prescribe eye drug (via New York Times)

CT scans help detect early lung cancer in smokers (via New York Times)

Biovail (now Valeant Pharmaceuticals (VRX) to hedge fund: I'm sorry! (via Pharmalot)

Roche melanoma drug show promise (via Reuters)

Conflict of interest rules: Going too far? Judging by the low quality of recent FDA advisory panels, the answer is definitely "yes!" (via Pharmalot)

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to

>To submit a news tip, send an email to:
Adam Feuerstein writes regularly for In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
CADX $0.00 0.00%
AVNR $16.96 0.00%
DNDN $0.06 -6.02%
BIIB $281.08 0.00%
BIOD $0.42 0.00%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs